Understanding G Protein-Coupled Receptors (GPCRs): Accelerating Discovery From Concept To Clinic.
Funder
National Health and Medical Research Council
Funding Amount
$6,871,789.00
Summary
G Protein-Coupled Receptors (GPCRs) form the largest family of receptors (and thus drug targets) in living organisms. Currently, the major reason that new drugs fail to reach the clinic is lack of appropriate drug effect (approx. 30%). Thus, we need a better understanding of how GPCRs work and how this relates to disease. Our Program addresses this knowledge gap, using GPCR models that are relevant to treatment of metabolic, cardiovascular and central nervous system disease.
Risk Stratification Of Older People In Hospital: Validation And Influence On Clinical Decision Making
Funder
National Health and Medical Research Council
Funding Amount
$291,067.00
Summary
Older people in hospital are at high risk of adverse outcomes, a vulnerability commonly referred to as frailty. In community-dwelling older people, frailty status can be measured precisely with a Frailty Index score. This research aims to develop a Frailty Index from a standardised comprehensive geriatric assessment instrument used in the routine care of many patients in hospital. This would assist clinicians to identify vulnerable older inpatients, improving their care in the acute setting.
Prospective Ovarian Cancer Cohort To Authenticate Stratification Of Prognosis In Ovarian Tumours (POCCA-SPOT)
Funder
National Health and Medical Research Council
Funding Amount
$993,580.00
Summary
Ovarian cancer has poor survival, with less than 40% of women surviving 5 years. There is a wide range of survival, but very few characteristics that indicate which patients will do well or poorly. We have developed a tumour test at diagnosis, that can predict prognosis at 5 years. In newly diagnosed cases, we will test tumours to predict prognosis and then determine the accuracy and assess patient acceptability. This study will lead to clinical use of the test and improve treatment decisions.
Validating Novel Biomarkers Relevant To Major Depression
Funder
National Health and Medical Research Council
Funding Amount
$515,550.00
Summary
Depression prevention and treatment are public health priorities; therefore, it is critical to improve and personalise treatments, which can only be achieved by advancing knowledge of its underlying biology. This research project will contribute to validating potentially relevant genes for MDD risk or antidepressant response and to provide the scientific foundation for future strategies to test their products as MDD biomarkers in the clinical setting.
Development And Validation Of A Latent Tuberculosis Diagnostic
Funder
National Health and Medical Research Council
Funding Amount
$534,865.00
Summary
Globally, tuberculosis is a leading cause of death with 9.6 million new diagnoses in 2014. The diagnosis of latent TB infection is important, but is difficult to make because current assays are suboptimal. We have developed a very simple assay which detects responses to TB antigens by co-expression of two surface markers expressed by CD4+ T cells. We propose to develop this into a highly standardised kit for the diagnosis of TB with our commercial partner Cytognos.
Validation Of A Multiplexed Blood Based Screening Assay For The Diagnosis Of Colorectal Cancer
Funder
National Health and Medical Research Council
Funding Amount
$556,712.00
Summary
Colorectal cancer (CRC) is the second most common cancer in Australia with poor patient outcome due to late detection of the disease. We have developed a simple blood based test that can diagnose individuals with CRC at an early stage when the chance of cure is greater than 80%.